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Look into the futures (genes that are directly involved in glycan assembly) are in the human genome
representing about 1–2% of the total genome. Over 40 human congenital diseases associated with glycogene
mutations have been described to date. It is almost certain that the causative glycogene mutations for many
more congenital diseases remain to be discovered. Some glycogenes are involved in the synthesis of only a
speciﬁc protein and/or a speciﬁc class of glycan whereas others play a role in the biosynthesis of more than
one glycan class. Mutations in the latter type of glycogene result in complex clinical phenotypes that present
difﬁcult diagnostic problems to the clinician. In order to understand in biochemical terms the clinical signs
and symptoms of a patient with a glycogene mutation, one must understand how the glycogene works. That
requires, ﬁrst of all, determination of the target protein or proteins of the glycogene followed by an
understanding of the role, if any, of the glycogene-dependent glycan in the functions of the protein. Many
glycogenes act on thousands of glycoproteins. There are unfortunately no general methods to identify all the
potentially large number of glycogene target proteins and which of these proteins are responsible for the
mutant phenotypes. Whereas biochemical methods have been highly successful in the discovery of
glycogenes responsible for many congenital diseases, it has more recently been necessary to use other
methods such as homozygosity mapping. Accurate diagnosis of many recently discovered diseases has
become difﬁcult and new diagnostic procedures must be developed. Last but not least is the lack of effective
treatment for most of these children and of animal models that can be used to test new therapies.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionGlycans are signiﬁcantly more complex than nucleic acids and
proteins, the other two major information-bearing biological macro-
molecules. Nucleic acids and proteins are linear molecules in which
the individual subunits (nucleotides and amino acids respectively) are
linked respectively by identical phospho-diester and peptide bonds. In
contrast, linkages between the individual carbohydrate subunits of
glycans are not all the same and the glycan polymers are commonly
branched rather than linear. The apparatus required for glycan
assembly is unique. Whereas the biosynthesis of nucleic acids and
proteins is carried out by relatively simple template mechanisms,
glycans require a complex non-template assembly line along which
many different enzymes and other proteinswork together tomake the
ﬁnal glycan product. The spectrum of all glycan structures – the
glycome – is immense; in humans, the number of glycan structures is
orders of magnitude greater than the number of proteins that are
encoded by the genome [1]. Francis Crick's original Central Dogma
ignored post-translational modiﬁcations (such as protein glycosyla-1 416 813 5022.
ll rights reserved.tion). It is now widely recognized that post-translational modiﬁca-
tions can greatly magnify the functions of a single gene [2,3]. This
review discusses the nature of glycogenes involved in glycan meta-
bolism, the extremely complex multi-systemic phenotypes that result
from congenital defects in glycogenes, the discovery of new glyco-
genes, and the diagnosis and treatment of glycogene diseases.
2. Glycogenes
At least half of all the proteins in the human genome are probably
N-glycosylated [4]. The number of genes directly involved in glycan
assembly (glycogenes [5,6]) in the human genome is large (∼250 to
500 genes representing ∼1–2% of the total number of human genes)
and encode many different types of protein: glycosyltransferases,
sulfotransferases that act on glycans, oligosaccharyltransferases,
nucleotide-sugar transporters and synthases, glycosidases, lectins,
genes required for the synthesis or utilization of dolichol-phosphate-
mannose and dolichol-phosphate-glucose, glycan ﬂippases, Con-
served Oligomeric Golgi (COG) complex proteins required for normal
trafﬁc in the Golgi apparatus, various kinases, mutases, isomerases
and other enzymes that act on carbohydrates, chaperones and other
proteins that ensure proper folding of glycogene-encoded proteins,
and probably many others. Although patients with congenital
abnormalities in glycan assembly (glycan biosynthesis and binding)
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with glycogene mutations have been described to date: 16 Type I
Congenital Disorders of Glycosylation (CDG-Ia to CDG-Ip) [7–14], 8
Type II CDGs (CDG-IIa to CDG-IIh) [7,15–19], 6 Congenital Muscular
Dystrophies (CMDs) [20], 2 involving GalNAcα1-O-Ser/Thr glycans
[21–24], 2 involving Fucα1-O-Ser/Thr glycans [25–28], 5 glycosami-
noglycan-related diseases [29–36], diseases involving defective glyco-
sphingolipid [37,38] and glycosylphosphatidylinositol [39] synthesis,
galactosemia [40–42], I-cell disease and pseudo-Hurler polydystrophy
(lysosomal storage diseases) caused by mutations in the gene
encoding UDP-N-acetylglucosamine:glycoprotein N-acetylglucosami-
nylphosphotransferase [43,44], and hereditary inclusion body myo-
pathy caused by mutations in the UDP-N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase (GNE) gene [45]. It is almost
certain that the causative glycogene mutations for many more
congenital diseases remain to be discovered.
Some glycogenes are involved in the synthesis of only a speciﬁc
protein and/or a speciﬁc class of glycan, e.g., the six genes involved in
the CMDs appear to act primarily on α-dystroglycan, and three of
these genes act only on Manα1-O-Ser/Thr-protein, i.e., the genes
encoding protein O-mannosyltransferases 1 and 2 (POMT1, POMT2)
and protein O-mannosyl β1,2-N-acetylglucosaminyltransferase I
(POMGNTI). Unlike the CDGs, these O-linked disorders possess dis-
tinctive muscle, eye, and brain phenotypes [46,47]. Peters'-plus syn-
drome is a rare autosomal recessive disorder involving defects in
multiple organ systems. The syndrome is a newly-discovered CDG due
to mutations in the β1,3-glucosyltransferase that adds glucose to
Fucα1-O-Ser/Thr to form a disaccharide speciﬁc to thrombospondin
type 1 repeats (TSRs). This disaccharide is only found on thrombos-
pondin 1 and a few other TSR-containing proteins [25].
On the other hand, many glycogenes are involved in the bio-
synthesis of more than one glycan class because the biosynthetic
pathways for glycosphingolipids and for protein-bound GlcNAcβ1-N-
Asn, GalNAcα1-O-Ser/Thr, Manα1-O-Ser/Thr, Fucα1-O-Ser/Thr and
Xylβ1-O-Ser (proteoglycans) glycans share glycogenes. For example,
several sialyl- [48,49], galactosyl- [50-52] and fucosyltransferases
[53–56] are common to two or more of the above pathways, as are
various nucleotide-sugar transporters and synthases, members of the
COG complex, and others.
Although the clinical presentations of “congenital glycosylation
diseases” (this term is used in a very general way in this chapter to
include CDGs, CMDs and other glycogene-deﬁcient congenital
diseases) may be quite distinct, clinical overlaps occur when muta-
tions occur in glycogenes common to more than one biosynthetic
pathway. The following CDGs clearly have the potential to involve
both N-glycans and other glycan types.
(i) Defective availability of dolichol-phospho-mannose (Dol-P-
Man): CDG-Ia (phosphomannomutase), -Ib (phosphomannose
isomerase), -Ie (Dol-P-Man synthase), -If (Dol-P-Man utiliza-
tion), -Im (dolichol kinase). However, since complete absence
of the Type I CDG pathway is lethal, these diseases are all due to
“leaky” (hypomorphic) mutations; therefore clinical symptoms
of diseases other than those of Type I CDG (e.g., CMD) are
unlikely to be visible.
(ii) Nucleotide-sugar transporter defects: CDG-IIc (GDP-Fuc trans-
porter), -IId (UDP-Gal transporter), -IIf (CMP-sialic acid
transporter).
(iii) Conserved Oligomeric Golgi (COG) complex proteins: CDG-IIe
(COG7), -IIg (COG1), -IIh (COG8). Defects in other COG subunits
are also likely to be found. The COG complex consists of 8 Golgi-
associated cytoplasmic proteins required for maintaining the
structure and function of the Golgi apparatus and for the
efﬁcient trafﬁcking of proteins within the Golgi and export out
of the Golgi [8,15–19,57]. Mutations in COG proteins therefore
alter the activities of glycosyltransferases, glycosidases, nucleo-tide-sugar transporters and other Golgi-localized proteins with
resultant defects in the biosynthesis of GlcNAcβ1-N-Asn,
GalNAcα1-O-Ser/Thr, Manα1-O-Ser/Thr (defective in the
CMDs) and other glycan types [58,59].
(iv) A groupofmentally retardeddysmorphic patientswith cutis laxa
(a condition characterized by sagging skin) probably represents
a novel CDG type with defects in either N-glycan or both N- and
O-glycan synthesis and an unusual cobblestone-like cortical
malformation over the frontal and parietal regions similar to the
lesions found in muscle-eye-brain type CMD [60,61]. Loss-
of-function mutations in the gene encoding a subunit of the
V-typeH+ATPase in several of these patients result in abnormal
glycosylation of serum proteins and cause an impairment of
Golgi trafﬁcking in ﬁbroblasts from affected individuals [62].
Proteins like the COG complex subunits and ATPases are not
“glycogenes” in the strict sense since they may be involved in
pathways other than glycosylation. Therefore the clinical presenta-
tions of such patients may contain elements that are not glycosyla-
tion-dependent.
3. How do glycogenes work?
In order to understand in biochemical terms the clinical signs and
symptoms of a patient with a glycogene mutation, one must under-
stand how the glycogene works. That requires, ﬁrst of all, determina-
tion of the target protein or proteins of the glycogene followed by an
understanding of the role, if any, of the glycogene-dependent glycan in
the functions of the protein. In the case of the CMDs (often called α-
dystroglycanopathies [63]), the target protein is known but the role of
the Manα1-O-Ser/Thr glycan in α-dystroglycan function is not clear.
The target protein problem becomes much more difﬁcult in the CDGs
because thousands of glycoproteins share the same glycan structures
and a mutation in a particular glycogene affects the glycosylation of
many proteins in most, if not all, cells in the body.
A classic approach to determination of gene target proteins and
functions is the creation of animals with null mutations in the gene
under study. Glycan function has been studied in many mutant
organisms: yeast [7,64], mice [3,65,66], ﬂies [67–69], worms [70–72],
zebraﬁsh [73,74] and, of course, human “congenital glycosylation
diseases”. The identities of some of the target proteins of a mutant
gene can be determined using mass spectrometry to compare glyco-
peptides isolated from wild type and mutant organisms [75]. How-
ever, only a relatively small number of glycogene target proteins can
be identiﬁed by current methods.
Taniguchi et al. [76] have reviewed their approach to the
identiﬁcation of target proteins of three glycosyltransferases involved
in N-glycan synthesis: β1,6-N-acetylglucosaminyltransferase V
(GlcNAcTV; adds a branch to the N-glycan core), β1,4-N-acetylgluco-
saminyltransferase III (GlcNAcTIII; adds the bisecting GlcNAc to the N-
glycan core), and α1,6-fucosyltransferase VIII (FucTVIII; adds a fucose
residue to the N-glycan core).
(i) GlcNAcTV has been shown to stimulate tumor metastasis in
mice [77]. Mammary tumor growth and metastases induced by
the polyomavirus middle T oncogene were considerably less in
GlcNAcTV-null mice than in transgenic littermates expressing
GlcNAcTV [77]. Matriptase (a metal-dependent serine pro-
tease) was identiﬁed as a GlcNAcTV target protein that
enhances cancer invasion and metastasis if a speciﬁc Asn
residue undergoes GlcNAcTV-dependent glycosylation [76].
(ii) E-cadherin, a homophilic adhesion molecule, has been identi-
ﬁed as a GlcNAcTIII target protein [76,78]. The addition of a
bisecting GlcNAc by GlcNAcTIII inhibits the action of GlcNAcTV
on the same N-glycan [79,80]. GlcNAcTIII overexpression has an
anti-metastatic effect thatmay be due, at least in part, to altered
N-glycan structures on E-cadherin [76,78].
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for FucTVIII [76]. FucTVIII down-regulation inhibits TGF-β
signaling resulting in increased production of several metallo-
proteinases (MMPs). The increased levels of MMPs in FucTVIII-
null mice cause emphysema-like degeneration of lung tissues
[81].
While these results are of great interest, it is important to note that
all three of the above enzymes also have many other target proteins
that may also play a role in the respective phenotypes. There is
unfortunately no general solution to identiﬁcation of all the poten-
tially large number of glycogene target proteins nor for the iden-
tiﬁcation of which protein(s) are responsible for the mutant
phenotypes. There is a very strong possibility that in many “congenital
glycosylation diseases”, it will not be possible to explain the pheno-
type on the basis of one or a small number of abnormally glycosylated
proteins.
Another aspect of the problem is a possibly deleterious role of
hypomorphic alleles and heterozygous mutations in the etiology of
disease. Sub-optimal glycosylation may have its impact in a larger
context and only under stressed conditions. Work with model
organisms is usually carried out with null mutants; perhaps we also
need to study the effects of hypomorphic and heterozygous mutations
in animal models.
Some pathology in glycosylation disorders is seen only when
environmental insult(s) collidewith the genetic insufﬁciency [82]. For
instance, protein-losing enteropathy (PLE, loss of plasma proteins
through the intestine) occurred in a CDG-Ic patient only during
periods of intestinal rotavirus infections [83]. CDG-Ib patients also
develop PLE in inﬂammatory settings [84]. The effects of proinﬂam-
matory cytokines and portal hypertension caused by their abnormal
liver architecture synergize with loss of heparan sulfate from the
intestinal epithelial cells and cascade into a PLE avalanche [82,85,86].
Even small decreases in glycosylation can be deleterious. Mice with
50% normal phosphomannose isomerase have no obvious phenotype,
but they show a signiﬁcant increase in enteric protein loss, which is
reversed by adding mannose to their drinking water. Increased pres-
sure and exposure to proinﬂammatory cytokines further exacerbates
protein leakage in these phosphomannose isomerase heterozygotes;
mannose reverses the glycosylation-related contribution [82].
4. Gene discovery and diagnosis
Discovery of glycogenes for novel “congenital glycosylation
diseases” and diagnosis of known diseases, especially of the Type 1
and some Type II Congenital Disorders of Glycosylation, have been
carried out for many years by various well-established biochemical
methods: (i) determination of protein-bound glycan structures, e.g.,
the GlcNAcβ1-N-Asn N-glycans present on serum transferrin and
other proteins by isoelectric focusing and mass spectrometry [87], (ii)
analysis of biochemical pathways in radio-labeled patient ﬁbroblasts
[88–91], and (iii) functional assays (if available) of the enzymes and
other proteins known to be involved in glycan synthesis [8].
More recently, a candidate gene approach in combination with
homozygosity mapping has been used to discover new disease-
causing glycogenes when consanguineous families are available. An
excellent example has been the discovery of some of the genes
involved in the heterogeneous Walker–Warburg Syndrome (WWS),
an autosomal recessive developmental disorder characterized by CMD
and complex brain and eye abnormalities. A genomewide linkage
analysis in 10 consanguineous families with WWS was reported in
2002 and indicated the existence of at least three WWS loci [92]. A
candidate-gene approach in combination with homozygosity map-
ping was subsequently carried out in 15 consanguineous families with
WWS [92]. On the basis of previous work on another CMD, the gene
encoding protein O-mannosyltransferase 1 (POMT1) was chosen as acandidate gene. Analysis of the locus for POMT1 revealed homo-
zygosity in 5 of 15 families. Sequencing of the POMT1 gene revealed
mutations in 6 of the 30 unrelated patients with WWS. A similar
homozygosity mapping approach reported in 2005 [93] identiﬁed
WWS patients with mutations in the gene encoding POMT2. Homo-
zygosity was found for the POMT2 locus at 14q24.3 in 4 of 11
consanguineous WWS families; homozygous POMT2 mutations were
present in two of these families as well as in one patient from another
cohort of sixWWS families. Mutations in four glycogenes are currently
known to causeWWS, i.e., the genes encoding POMT1, POMT2, fukutin
and fukutin related protein (FKRP) [94]. These four genes account for
approximately one third of theWWS cases indicating that otherWWS
genes remain to be discovered [93].
Homozygosity mapping methods were also used in the discovery
of the defective β1,3-glucosyltransferase glycogene in Peters'-plus
syndrome (see above) [25], of the V-type H+ ATPase-dependent CDG
(see above) [60,62], and of the role of a mutant oligosaccharyltrans-
ferase subunit in autosomal-recessive nonsyndromic mental retarda-
tion [10,11]. Homozygosity mapping is a powerful method of gene
discovery if consanguineous families are available. The biochemical
methods that served so well in the early days of CDG discovery are
often not successful in the more complex “congenital glycosylation
diseases” but will remain an important part of the tool box to
understand the mechanisms of action and biology of the glycogenes
being discovered by other methods.
Many patients with “congenital glycosylation diseases” have been
reported in which the function of the mutant gene is not known or in
which no gene locus has as yet been identiﬁed [7,8,95–97]. For
example, three CMD genes have no known function: fukutin [98],
fukutin-related protein (FKRP) [99] and LARGE [100]. A long-
standing puzzle is hereditary erythroblastic multinuclearity with a
positive acidiﬁed-serum lysis test (HEMPAS; congenital dyserythro-
poietic anemia type II). HEMPAS presents as a relatively mild genetic
dyserythropoietic anemia caused by an unknown glycosylation
defect [101–103]. Erythrocyte membrane glycoproteins, such as
band 3 and band 4.5, which are normally glycosylated with
polylactosamines lack these carbohydrates in HEMPAS. Polylactosa-
mines accumulate as glycolipids in HEMPAS erythrocytes. Analysis of
N-glycans from HEMPAS erythrocyte membranes revealed a series of
incompletely processed N-glycan structures. Linkage analysis of
HEMPAS cases from southern Italy have excluded two long-suspected
candidate genes (encoding α-mannosidase II and GlcNAc-transferase
II) as the causative gene, but identiﬁed a gene on chromosome 20q11
[104–106].
The problem of accurate diagnosis of “congenital glycosylation
diseases” has become more difﬁcult due to the rapid rate of discovery
of new glycogenes that do not ﬁt neatly into the pattern of genes
involved primarily in N-glycan biosynthesis. Some patients do not
show an abnormal serum transferrin, the classic screening test for
CDGs, e.g., autosomal-recessive nonsyndromic mental retardation
associated with a mutant oligosaccharyltransferase, defects in the
GDP-fucose and CMP-Sia transporters and in glucosidase I, and in
some cases of phosphomannomutase deﬁciency (CDG-Ia).
The diversity of proteins that can be affected by a glycogene
mutation results in defective development of multiple organ systems
(brain, gastrointestinal tract, liver, vision, and the endocrine and
immune systems). The biochemically and clinically heterogeneous
pictures of these patients indicate the importance of normal glyco-
sylation in these organs and present difﬁcult diagnostic problems to
the clinician. It is clear that the current diagnostic approaches have to
be expanded and that some of these methods may have to target only
one or a few glycogenes.
There are many surprises waiting for us and we should consider a
“congenital glycosylation disease” in every new clinical presentation
and also in all known clinical syndromes in which the basic defect
remains unknown.
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A serious problem for CDG and other glycogene-deﬁcient patients,
many of whom are desperately non-functional, is the lack of effective
treatments. Only two CDG subtypes, CDG-Ib and CDG-IIc, have been
treated successfully [107]. In CDG-Ib, alimentary addition of mannose
bypasses the defective step (conversion of fructose-6-phosphate to
mannose-6-phosphate) by allowing for formation of mannose-6-
phosphate via the action of hexokinase. These children show
remarkable improvement with therapy, probably because there are
no detectable neuronal abnormalities in this disease. CDG-IIc, also
known as leukocyte adhesion deﬁciency type II (LAD-II), stems from a
defective membrane transport of GDP-L-Fuc. Alimentary supplemen-
tation with L-fucose in one CDG-IIc patient corrected the immuno-
logical defect and, surprisingly, also improved the neurological
symptoms. However, treatment was ineffective in three other CDG-
IIc patients probably due to differences in mutations between the
patients.
Although mannose treatment of ﬁbroblasts from CDG-Ia patients,
the most common form of CDG, corrects altered N-glycosylation due
to the absence of phosphomannomutase (the enzyme that converts
Man-6-phosphate to Man-1-phosphate) [90,91,108], oral adminis-
tration of Man to these patents is unfortunately not effective [107].
Oral administration of Man-1-phosphate is also not effective
because this material is not transported across the cell membrane.
Attempts have been made to synthesize cell-permeable compounds
that would be converted to free Man-1-phosphate upon entry into
the cell [107]. Although such compounds correct the biochemical
phenotype of CDG-Ia ﬁbroblasts, the compounds synthesized to date
are too unstable and too toxic to be useful in the clinic. Another
approach to therapy is enzyme replacement, i.e., systemic delivery
of normal versions of the mutant enzyme (e.g., phosphomannomu-
tase) [107].
There is currently a lack of Type I CDG animal models that can be
used to test putative therapeutic agents. Complete lack of N-
glycosylation is lethal in all eukaryotes and null mutations in the
glycogenes defective in Type I CDGs are embryonic lethal in humans
and mice. All Type I CDG patients have hypomorphic mutations and
retain the ability to synthesize reduced amounts of normal N-glycans.
Animal models for the Type I CDGs would therefore need to be
hypomorphic mutants.
Therapy of CDG-Ib patients is effective partly because these
patients do not have the severe abnormalities present in most other
forms of Type I CDG (psychomotor retardation, retinopathy, and
muscular hypotonia). This damage is probably established during fetal
development and therefore may not be reversible with postpartum
treatment. However, recent studies on neuroplasticity suggest that the
brain and nervous system are capable of considerable repair in both
children and adults.
Hyperglycosylation strategies have been proposed as therapeutic
interventions in the CMDs (α-dystroglycanopathies) [20,109–111].
Recent work has demonstrated that the overexpression of either one
of two related glycogenes, LARGE and LARGE2, results in the
hyperglycosylation of α-dystroglycan and resultant restoration of
normal α-dystroglycan ligand binding. The mechanism of this
important therapeutic effect has not been determined.
6. Conclusions
We have attempted in this relatively brief review to present a
picture of the highly complicated nature of glycan structure and
assembly and the devastating effects of glycogenemalfunctions on the
human body.Whereas spectacular advances have beenmade in recent
years in the discovery of new glycogenes and the phenotypes of the
diseases resulting from defects in these genes, a great deal of work
remains to be done especially in the areas of diagnosis and treatment.Acknowledgments
Supported by the Canadian Institutes for Health Research (CIHR) to
HS and by NIH grant R01 DK55615 and the Children's Hearts Fund to
HF.
References
[1] H.H. Freeze, Genetic defects in the human glycome, Nat. Rev. Genet. 7 (2006)
537–551.
[2] R.G. Krishna, F. Wold, Post-translational modiﬁcation of proteins, Adv. Enzymol.
Relat. Areas Mol. Biol. 67 (1993) 265–298.
[3] J.B. Lowe, J.D. Marth, A genetic approach to mammalian glycan function, Annu.
Rev. Biochem. 72 (2003) 643–691.
[4] R. Apweiler, H. Hermjakob, N. Sharon, On the frequency of protein glycosylation,
as deduced from analysis of the SWISS-PROT database, Biochim. Biophys. Acta
1473 (1999) 4–8.
[5] N. Kikuchi, H. Narimatsu, Bioinformatics for comprehensive ﬁnding and analysis
of glycosyltransferases, Biochim. Biophys. Acta 1760 (2006) 578–583.
[6] H. Narimatsu, Human glycogene cloning: focus on beta 3-glycosyltransferase and
beta 4-glycosyltransferase families, Curr. Opin. Struct. Biol. 16 (2006) 567–575.
[7] H.H. Freeze, M. Aebi, Altered glycan structures: the molecular basis of congenital
disorders of glycosylation, Curr. Opin. Struct. Biol. 15 (2005) 490–498.
[8] H.H. Freeze, Congenital disorders of glycosylation: CDG-I, CDG-II, and beyond,
Curr. Mol. Med. 7 (2007) 389–396.
[9] C. Kranz, C. Jungeblut, J. Denecke, A. Erlekotte, C. Sohlbach, V. Debus, H.G. Kehl, E.
Harms, A. Reith, S. Reichel, et al., A defect in dolichol phosphate biosynthesis
causes a new inherited disorder with death in early infancy, Am. J. Hum. Genet.
80 (2007) 433–440.
[10] F. Molinari, F. Foulquier, P.S. Tarpey, W. Morelle, S. Boissel, J. Teague, S. Edkins, P.A.
Futreal, M.R. Stratton, G. Turner, et al., Oligosaccharyltransferase-subunit
mutations in nonsyndromic mental retardation, Am. J. Hum. Genet. 82 (2008)
1150–1157.
[11] M. Garshasbi, V. Hadavi, H. Habibi, K. Kahrizi, R. Kariminejad, F. Behjati, A.
Tzschach, H. Najmabadi, H.H. Ropers, A.W. Kuss, A defect in the TUSC3 gene is
associated with autosomal recessive mental retardation, Am. J. Hum. Genet. 82
(2008) 1158–1164.
[12] C.G. Frank, S. Sanyal, J.S. Rush, C.J. Waechter, A.K. Menon, Does Rft1 ﬂip an
N-glycan lipid precursor? Nature 454 (2008) E3–E4 discussion E4–5.
[13] S. Sanyal, C.G. Frank, A.K. Menon, Distinct ﬂippases translocate glycerophos-
pholipids and oligosaccharide diphosphate dolichols across the endoplasmic
reticulum, Biochemistry 47 (2008) 7937–7946.
[14] M.A. Haeuptle, F.M. Pujol, C. Neupert, B. Winchester, A.J. Kastaniotis, M. Aebi, T.
Hennet, Human RFT1 deﬁciency leads to a disorder of N-linked glycosylation,
Am. J. Hum. Genet. 82 (2008) 600–606.
[15] C. Kranz, B.G. Ng, L. Sun, V. Sharma, E.A. Eklund, Y. Miura, D. Ungar, V. Lupashin,
R.D. Winkel, J.F. Cipollo, et al., COG8 deﬁciency causes new congenital disorder
of glycosylation type IIh, Hum. Mol. Genet. 16 (2007) 731–741.
[16] F. Foulquier, D. Ungar, E. Reynders, R. Zeevaert, P. Mills, M.T. Garcia-Silva, P.
Briones, B. Winchester, W. Morelle, M. Krieger, et al., A new inborn error of
glycosylation due to a Cog8 deﬁciency reveals a critical role for the Cog1–
Cog8 interaction in COG complex formation, Hum. Mol. Genet. 16 (2007)
717–730.
[17] F. Foulquier, E. Vasile, E. Schollen, N. Callewaert, T. Raemaekers, D. Quelhas, J.
Jaeken, P. Mills, B. Winchester, M. Krieger, et al., Conserved oligomeric Golgi
complex subunit 1 deﬁciency reveals a previously uncharacterized congenital
disorder of glycosylation type II, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
3764–3769.
[18] R. Zeevaert, F. Foulquier, J. Jaeken, G. Matthijs, Deﬁciencies in subunits of the
Conserved Oligomeric Golgi (COG) complex deﬁne a novel group of Congenital
Disorders of Glycosylation, Mol. Genet. Metab. 93 (2008) 15–21.
[19] X. Wu, R.A. Steet, O. Bohorov, J. Bakker, J. Newell, M. Krieger, L. Spaapen, S.
Kornfeld, H.H. Freeze, Mutation of the COG complex subunit gene COG7 causes a
lethal congenital disorder, Nat. Med. 10 (2004) 518–523.
[20] P.T. Martin, Congenital muscular dystrophies involving the O-mannose pathway,
Curr. Mol. Med. 7 (2007) 417–425.
[21] A.M. Barbieri, M. Filopanti, G. Bua, P. Beck-Peccoz, Two novel nonsensemutations
in GALNT3 gene are responsible for familial tumoral calcinosis, J. Hum. Genet. 52
(2007) 464–468.
[22] H.J. Garringer, S.M. Mortazavi, F. Esteghamat, M. Malekpour, H. Boztepe, R.
Tanakol, S.I. Davis, K.E. White, Two novel GALNT3 mutations in familial tumoral
calcinosis, Am. J. Med. Genet. A. 143A (2007) 2390–2396.
[23] O. Topaz, D.L. Shurman, R. Bergman, M. Indelman, P. Ratajczak, M. Mizrachi, Z.
Khamaysi, D. Behar, D. Petronius, V. Friedman, et al., Mutations in GALNT3,
encoding a protein involved in O-linked glycosylation, cause familial tumoral
calcinosis, Nat. Genet. 36 (2004) 579–581.
[24] T. Ju, R.D. Cummings, Protein glycosylation: chaperone mutation in Tn syndrome,
Nature 437 (2005) 1252.
[25] T.Y. Heinonen, M. Maki, Peters'-plus syndrome is a congenital disorder of
glycosylation caused by a defect in the beta1,3-glucosyltransferase that modiﬁes
thrombospondin type 1 repeats, Ann. Med. (2008) 1–9.
[26] R. Rampal, K.B. Luther, R.S. Haltiwanger, Notch signaling in normal and disease
states: possible therapies related to glycosylation, Curr. Mol. Med. 7 (2007)
427–445.
929H. Schachter, H.H. Freeze / Biochimica et Biophysica Acta 1792 (2009) 925–930[27] D.B. Sparrow, G. Chapman, M.A. Wouters, N.V. Whittock, S. Ellard, D. Fatkin, P.D.
Turnpenny, K. Kusumi, D. Sillence, S.L. Dunwoodie, Mutation of the Lunatic Fringe
gene in humans causes spondylocostal dysostosis with a severe vertebral
phenotype, Am. J. Hum. Genet. 78 (2006) 28–37.
[28] E. Ladi, J.T. Nichols, W. Ge, A. Miyamoto, C. Yao, L.T. Yang, J. Boulter, Y.E. Sun, C.
Kintner, G. Weinmaster, The divergent DSL ligand Dll3 does not activate Notch
signaling but cell autonomously attenuates signaling induced by other DSL
ligands, J. Cell Biol. 170 (2005) 983–992.
[29] K. Furukawa, T. Okajima, Galactosyltransferase I is a gene responsible for
progeroid variant of Ehlers–Danlos syndrome: molecular cloning and identiﬁca-
tion of mutations, Biochim. Biophys. Acta 1573 (2002) 377–381.
[30] B.M. Zak, B.E. Crawford, J.D. Esko, Hereditary multiple exostoses and heparan
sulfate polymerization, Biochim. Biophys. Acta 1573 (2002) 346–355.
[31] T.O. Akama, K. Nishida, J. Nakayama, H.Watanabe, K. Ozaki, T. Nakamura, A. Dota,
S. Kawasaki, Y. Inoue, N. Maeda, et al., Macular corneal dystrophy type I and type
II are caused by distinct mutations in a new sulphotransferase gene, Nat. Genet.
26 (2000) 237–241.
[32] N.P. Liu, S. Dew-Knight, M. Rayner, F. Jonasson, T.O. Akama, M.N. Fukuda, W. Bao,
J.R. Gilbert, J.M. Vance, G.K. Klintworth, Mutations in corneal carbohydrate
sulfotransferase 6 gene (CHST6) cause macular corneal dystrophy in Iceland,
Mol. Vis. 6 (2000) 261–264.
[33] M.F. El-Ashry, M.M. Abd El-Aziz, S. Wilkins, M.E. Cheetham, S.E. Wilkie, A.J.
Hardcastle, S. Halford, A.Y. Bayoumi, L.A. Ficker, S. Tuft, et al., Identiﬁcation of
novel mutations in the carbohydrate sulfotransferase gene (CHST6) causing
macular corneal dystrophy, Invest. Ophthalmol. Vis. Sci. 43 (2002) 377–382.
[34] M.H. van Roij, S. Mizumoto, S. Yamada, T. Morgan, M.B. Tan-Sindhunata, H.
Meijers-Heijboer, J.I. Verbeke, D. Markie, K. Sugahara, S.P. Robertson, Spondy-
loepiphyseal dysplasia, Omani type: further deﬁnition of the phenotype, Am. J.
Med. Genet. A. 146A (2008) 2376–2384.
[35] P. Hermanns, S. Unger, A. Rossi, A. Perez-Aytes, H. Cortina, L. Bonafe, L. Boccone, V.
Setzu, M. Dutoit, L. Sangiorgi, et al., Congenital joint dislocations caused by
carbohydrate sulfotransferase 3 deﬁciency in recessive Larsen syndrome and
humero-spinal dysostosis, Am. J. Hum. Genet. 82 (2008) 1368–1374.
[36] H. Thiele, M. Sakano, H. Kitagawa, K. Sugahara, A. Rajab, W. Hohne, H. Ritter, G.
Leschik, P. Nurnberg, S. Mundlos, Loss of chondroitin 6-O-sulfotransferase-1
function results in severe human chondrodysplasia with progressive spinal
involvement, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10155–10160.
[37] F. Farukhi, C. Dakkouri, H. Wang, M. Wiztnitzer, E.I. Traboulsi, Etiology of vision
loss in ganglioside GM3 synthase deﬁciency, Ophthalmic. Genet. 27 (2006)
89–91.
[38] M.A. Simpson, H. Cross, C. Proukakis, D.A. Priestman, D.C. Neville, G.
Reinkensmeier, H. Wang, M. Wiznitzer, K. Gurtz, A. Verganelaki, et al.,
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-
of-function mutation of GM3 synthase, Nat. Genet. 36 (2004) 1225–1229.
[39] T. Kinoshita, N. Inoue, J. Takeda, Defective glycosyl phosphatidylinositol anchor
synthesis and paroxysmal nocturnal hemoglobinuria, in: F.J. Dixon (Ed.),
Advances in Immunology, Vol 60, Academic Press Inc, 1995, pp. 57–103.
[40] L. Sturiale, R. Barone, A. Palmigiano, C.N. Ndosimao, P. Briones, M. Adamowicz, J.
Jaeken, D. Garozzo, Multiplexed glycoproteomic analysis of glycosylation
disorders by sequential yolk immunoglobulins immunoseparation and MALDI-
TOF MS, Proteomics 8 (2008) 3822–3832.
[41] L. Sturiale, R. Barone, A. Fiumara, M. Perez, M. Zaffanello, G. Sorge, L. Pavone, S.
Tortorelli, J.F. O'Brien, J. Jaeken, et al., Hypoglycosylation with increased
fucosylation and branching of serum transferrin N-glycans in untreated
galactosemia, Glycobiology 15 (2005) 1268–1276.
[42] J. Charlwood, P. Clayton, G. Keir, N. Mian, B. Winchester, Defective galactosylation
of serum transferrin in galactosemia, Glycobiology 8 (1998) 351–357.
[43] M.L. Reitman, A. Varki, S. Kornfeld, Fibroblasts from patients with I-cell disease
and pseudo-Hurler polydystrophy are deﬁcient in uridine 5(-diphosphate-N-
acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase
activity, J. Clin. Invest. 67 (1981) 1574–1579.
[44] S. Kornfeld, Trafﬁcking of lysosomal enzymes in normal and disease states, J. Clin.
Invest. 77 (1986) 1–6.
[45] M.C. Malicdan, S. Noguchi, I. Nishino, Perspectives on distal myopathy with
rimmed vacuoles or hereditary inclusion body myopathy: contributions from an
animal model. Lack of sialic acid, a central determinant in sugar chains, causes
myopathy? Acta Myol. 26 (2007) 171–175.
[46] P.T. Martin, The dystroglycanopathies: the new disorders of O-linked glycosyla-
tion, Semin. Pediatr. Neurol. 12 (2005) 152–158.
[47] T. Endo, Aberrant glycosylation of alpha-dystroglycan and congenital muscular
dystrophies, Acta Myol. 24 (2005) 64–69.
[48] T. Hamamoto, S. Tsuji, ST3Gal-II (SAT-IV), in: N. Taniguchi, K. Honke, M. Fukuda
(Eds.), Handbook of Glycosyltransferases and Related Genes, Springer-Verlag,
2002, pp. 274–278.
[49] T. Hamamoto, S. Tsuji, ST6Gal-I, in: N. Taniguchi, K. Honke, M. Fukuda (Eds.),
Handbook of Glycosyltransferases and Related Genes, Springer-Verlag, 2002,
pp. 295–299.
[50] N.L. Shaper, J.H. Shaper, β4-Galactosyltransferase-I, in: N. Taniguchi, K. Honke, M.
Fukuda (Eds.), Handbook of Glycosyltransferases and Related Genes, Springer-
Verlag, 2002, pp. 11–19.
[51] K. Furukawa, H. Clausen, β4-Galactosyltransferase-II, -III, -IV, -V, -VI, and -VII, in:
N. Taniguchi, K. Honke, M. Fukuda (Eds.), Handbook of Glycosyltransferases and
Related Genes, Springer-Verlag, 2002, pp. 20–26.
[52] T. Hennet, E.G. Berger, β3-Galactosyltransferase-I, -II, and -III, in: N. Taniguchi, K.
Honke, M. Fukuda (Eds.), Handbook of Glycosyltransferases and Related Genes,
Springer-Verlag, 2002, pp. 27–32.[53] R. Oriol, R. Mollicone, α2-Fucosyltransferases (FUT1, FUT2, and Sec1), in: N.
Taniguchi, K. Honke, M. Fukuda (Eds.), Handbook of Glycosyltransferases and
Related Genes, Springer-Verlag, 2002, pp. 205–217.
[54] H. Narimatsu, α3/4-Fucosyltransferase (FUT3, Lewis enzyme), in: N. Taniguchi,
K. Honke, M. Fukuda (Eds.), Handbook of Glycosyltransferases and Related
Genes, Springer-Verlag, 2002, pp. 218–225.
[55] H. Narimatsu, α3-Fucosyltransferase-IV (FUT4), in: N. Taniguchi, K. Honke, M.
Fukuda (Eds.), Handbook of Glycosyltransferases and Related Genes, Springer-
Verlag, 2002, pp. 226–231.
[56] R. Kannagi, α3-Fucosyltransferase-VI (FUT6), in: N. Taniguchi, K. Honke, M.
Fukuda (Eds.), Handbook of Glycosyltransferases and Related Genes, Springer-
Verlag, 2002, pp. 237–245.
[57] D. Ungar, T. Oka, M. Krieger, F.M. Hughson, Retrograde transport on the COG
railway, Trends Cell. Biol. 16 (2006) 113–120.
[58] S.Wopereis, D.J. Lefeber, E. Morava, R.A.Wevers, Mechanisms in protein O-glycan
biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis
defects: a review, Clin. Chem. 52 (2006) 574–600.
[59] J.M. Percival, S.C. Froehner, Golgi complex organization in skeletal muscle: a role
for Golgi-mediated glycosylation in muscular dystrophies? Trafﬁc 8 (2007)
184–194.
[60] L. Van Maldergem, M. Yuksel-Apak, H. Kayserili, E. Seemanova, S. Giurgea, L.
Basel-Vanagaite, E. Leao-Teles, J. Vigneron, M. Foulon, M. Greally, et al.,
Cobblestone-like brain dysgenesis and altered glycosylation in congenital cutis
laxa, Debre type, Neurology 71 (2008) 1602–1608.
[61] S. Wopereis, E. Morava, S. Grunewald, P.B. Mills, B.G. Winchester, P. Clayton, P.
Coucke, K.M. Huijben, R.A. Wevers, A combined defect in the biosynthesis of N-
and O-glycans in patients with cutis laxa and neurological involvement: the
biochemical characteristics, Biochim. Biophys. Acta 1741 (2005) 156–164.
[62] U. Kornak, E. Reynders, A. Dimopoulou, J. van Reeuwijk, B. Fischer, A. Rajab, B.
Budde, P. Nurnberg, F. Foulquier, D. Lefeber, et al., Impaired glycosylation and
cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2,
Nat. Genet. 40 (2008) 32–34.
[63] T. Toda, K. Kobayashi, S. Takeda, J. Sasaki, H. Kurahashi, H. Kano, M. Tachikawa, F.
Wang, Y. Nagai, K. Taniguchi, et al., Fukuyama-type congenital muscular
dystrophy (FCMD) and alpha-dystroglycanopathy, Congenit. Anom. Kyoto 43
(2003) 97–104.
[64] L. Lehle, S. Strahl, W. Tanner, Protein glycosylation, conserved from yeast to man:
a model organism helps elucidate congenital human diseases, Angew. Chem. Int.
Ed. Engl. 45 (2006) 6802–6818.
[65] K. Angata, W. Lee, J. Mitoma, J.D. Marth, M. Fukuda, Cellular and molecular
analysis of neural development of glycosyltransferase gene knockout mice,
Methods Enzymol. 417 (2006) 25–37.
[66] K. Ohtsubo, J.D. Marth, Glycosylation in cellular mechanisms of health and
disease, Cell 126 (2006) 855–867.
[67] R. Leonard, D. Rendic, C. Rabouille, I.B. Wilson, T. Preat, F. Altmann, The Drosophila
fused lobes gene encodes an N-acetylglucosaminidase involved in N-glycan
processing, J. Biol. Chem. 281 (2006) 4867–4875.
[68] M. Sarkar, P.A. Leventis, C.I. Silvescu, V.N. Reinhold, H. Schachter, G.L. Boulianne,
Null mutations in Drosophila N-acetylglucosaminyltransferase I produce defects
in locomotion and a reduced lifespan, J. Biol. Chem. 281 (2006) 12776–12785.
[69] A. Seppo, P. Matani, M. Sharrow, M. Tiemeyer, Induction of neuron-speciﬁc
glycosylation by Tollo/Toll-8, a Drosophila Toll-like receptor expressed in non-
neural cells, Development 130 (2003) 1439–1448.
[70] J.F. Cipollo, A.M. Awad, C.E. Costello, C.B. Hirschberg, srf-3, a mutant of
Caenorhabditis elegans, resistant to bacterial infection and to bioﬁlm binding,
is deﬁcient in glycoconjugates, J. Biol. Chem. 279 (2004) 52893–52903.
[71] H. Schachter, Protein glycosylation lessons from Caenorhabditis elegans, Curr.
Opin. Struct. Biol. 14 (2004) 607–616.
[72] H. Shi, J. Tan, H. Schachter, N-glycans are involved in the response of Caenorhabditis
elegans to bacterial pathogens, Methods Enzymol. 417 (2006) 359–389.
[73] Q.J. Machingo, A. Fritz, B.D. Shur, A beta1,4-galactosyltransferase is required for
Bmp2-dependent patterning of the dorsoventral axis during zebraﬁsh embry-
ogenesis, Development 133 (2006) 2233–2241.
[74] Q.J. Machingo, A. Fritz, B.D. Shur, A beta1,4-galactosyltransferase is required for
convergent extension movements in zebraﬁsh, Dev. Biol. 297 (2006) 471–482.
[75] J. Tan, H. Shi, H. Schachter, Functional glycoproteomic analysis of Caenorhabditis
elegans interaction with bacterial pathogens, Glycobiology 16 (2006) 1112.
[76] N. Taniguchi, E. Miyoshi, J. Gu, K. Honke, A. Matsumoto, Decoding sugar functions
by identifying target glycoproteins, Curr. Opin. Struct. Biol. 16 (2006) 561–566.
[77] M. Granovsky, J. Fata, J. Pawling, W.J. Muller, R. Khokha, J.W. Dennis, Suppression
of tumor growth and metastasis in Mgat5-deﬁcient mice, Nat. Med. 6 (2000)
306–312.
[78] M. Yoshimura, Y. Ihara, Y. Matsuzawa, N. Taniguchi, Aberrant glycosylation of
E-cadherin enhances cell–cell binding to suppress metastasis, J. Biol. Chem. 271
(1996) 13811–13815.
[79] H. Schachter, Biosynthetic controls that determine the branching and micro-
heterogeneity of protein-bound oligosaccharides, Biochem. Cell. Biol. 64 (1986)
163–181.
[80] H. Schachter, Coordination between enzyme speciﬁcity and intracellular
compartmentation in the control of protein-bound oligosaccharide biosynthesis,
Biol. Cell 51 (1984) 133–145.
[81] X. Wang, S. Inoue, J. Gu, E. Miyoshi, K. Noda, W. Li, Y. Mizuno-Horikawa, M.
Nakano, M. Asahi, M. Takahashi, et al., Dysregulation of TGF-beta1 receptor
activation leads to abnormal lung development and emphysema-like phenotype
in core fucose-deﬁcient mice, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
15791–15796.
930 H. Schachter, H.H. Freeze / Biochimica et Biophysica Acta 1792 (2009) 925–930[82] L. Bode, H.H. Freeze, Applied glycoproteomics—approaches to study genetic-
environmental collisions causing protein-losing enteropathy, Biochim. Biophys.
Acta 1760 (2006) 547–559.
[83] V. Westphal, S. Murch, S. Kim, G. Srikrishna, B. Winchester, R. Day, H.H. Freeze,
Reduced heparan sulfate accumulation in enterocytes contributes to protein-
losing enteropathy in a congenital disorder of glycosylation, Am. J. Pathol. 157
(2000) 1917–1925.
[84] R. Niehues, M. Hasilik, G. Alton, C. Körner, M. Schiebe-Sukumar, H.G. Koch, K.P.
Zimmer, R.R. Wu, E. Harms, K. Reiter, et al., Carbohydrate-deﬁcient glycoprotein
syndrome type Ib — phosphomannose isomerase deﬁciency and mannose
therapy, J. Clin. Invest. 101 (1998) 1414–1420.
[85] L. Bode, S. Murch, H.H. Freeze, Heparan sulfate plays a central role in a dynamic in
vitro model of protein-losing enteropathy, J. Biol. Chem. 281 (2006) 7809–7815.
[86] L. Bode, E.A. Eklund, S. Murch, H.H. Freeze, Heparan sulfate depletion ampliﬁes
TNF-alpha-induced protein leakage in an in vitro model of protein-losing
enteropathy, Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G1015–1023.
[87] Y. Wada, Mass spectrometry for congenital disorders of glycosylation, CDG,
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 838 (2006) 3–8.
[88] S. Kim, V. Westphal, G. Srikrishna, D.P. Mehta, S. Peterson, J. Filiano, P.S. Karnes,
M.C. Patterson, H.H. Freeze, Dolichol phosphate mannose synthase (DPM1)
mutations deﬁne congenital disorder of glycosylation Ie (CDG-Ie), J. Clin. Invest.
105 (2000) 191–198.
[89] X. Wu, J.S. Rush, D. Karaoglu, D. Krasnewich, M.S. Lubinsky, C.J. Waechter, R.
Gilmore, H.H. Freeze, Deﬁciency of UDP-GlcNAc:dolichol phosphate N-acet-
ylglucosamine-1 phosphate transferase (DPAGT1) causes a novel congenital
disorder of glycosylation Type Ij, Hum. Mutat. 22 (2003) 144–150.
[90] J.S. Rush, K. Panneerselvam, C.J. Waechter, H.H. Freeze, Mannose supplementa-
tion corrects GDP-mannose deﬁciency in cultured ﬁbroblasts from some patients
with Congenital Disorders of Glycosylation (CDG), Glycobiology 10 (2000)
829–835.
[91] K. Panneerselvam, J.R. Etchison, H.H. Freeze, Human ﬁbroblasts prefer mannose
over glucose as a source of mannose for N-glycosylation. Evidence for the
functional importance of transported mannose, J. Biol. Chem. 272 (1997)
23123–23129.
[92] D. Beltran-Valero de Bernabe, S. Currier, A. Steinbrecher, J. Celli, E. van Beusekom,
B. van der Zwaag, H. Kayserili, L. Merlini, D. Chitayat, W.B. Dobyns, et al.,
Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe
neuronal migration disorder Walker–Warburg syndrome, Am. J. Hum. Genet. 71
(2002) 1033–1043.
[93] J. van Reeuwijk, M. Janssen, C. van den Elzen, D. Beltran-Valero de Bernabe, P.
Sabatelli, L. Merlini, M. Boon, H. Scheffer, M. Brockington, F. Muntoni, et al.,
POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker–
Warburg syndrome, J. Med. Genet. 42 (2005) 907–912.
[94] J. Vajsar, H. Schachter, Walker–Warburg syndrome, Orphanet. J. Rare Dis. 1
(2006) 29.
[95] H.H. Freeze, Novel perspectives on glycosylation and human disease, Curr. Mol.
Med. 7 (2007) 387.[96] J. Jaeken, G. Matthijs, Congenital disorders of glycosylation: a rapidly expanding
disease family, Annu. Rev. Genomics Hum. Genet. 8 (2007) 261–278.
[97] E. Morava, H. Wosik, J. Karteszi, M. Guillard, M. Adamowicz, J. Sykut-Cegielska, K.
Hadzsiev, R.A. Wevers, D.J. Lefeber, Congenital disorder of glycosylation type Ix:
review of clinical spectrum and diagnostic steps, J. Inherit. Metab. Dis. 31 (2008)
450–456.
[98] T. Toda, T. Chiyonobu, H. Xiong, M. Tachikawa, K. Kobayashi, H. Manya, S. Takeda,
M. Taniguchi, H. Kurahashi, T. Endo, Fukutin and alpha-dystroglycanopathies,
Acta Myol. 24 (2005) 60–63.
[99] H. Schachter, J. Vajsar, W. Zhang, The role of defective glycosylation in congenital
muscular dystrophy, Glycoconj. J. 20 (2004) 291–300.
[100] P.K. Grewal, J.E. Hewitt, Glycosylation defects: a new mechanism for muscular
dystrophy? Hum. Mol. Genet. 12 Spec No 2 (2003) R259–R264.
[101] H. Schachter, Congenital disorders involving defective N-glycosylation of
proteins, Cell. Mol. Life Sci. 58 (2001) 1085–1104.
[102] M.N. Fukuda, Diseases with deﬁciencies in asparagine-linked glycosylation. B.
Congenital dyserythropoietic anemia type II (HEMPAS), in: M. Fukuda, O.
Hindsgaul (Eds.), Molecular and Cellular Glycobiology, Oxford University Press,
2000, pp.158–168, Hames BD, Glover DM (Series Editors): Frontiers inMolecular
Biology, 30.
[103] M.N. Fukuda, HEMPAS. Hereditary erythroblastic multinuclearity with positive
acidiﬁed serum lysis test, Biochim. Biophys. Acta 1455 (1999) 231–239.
[104] C. Lanzara, R. Ficarella, A. Totaro, X. Chen, R. Roberto, S. Perrotta, C. Lasalandra, P.
Gasparini, A. Iolascon, M. Carella, Congenital dyserythropoietic anemia type II:
exclusion of seven candidate genes, Blood Cells Mol. Dis. 30 (2003) 22–29.
[105] A. Iolascon, V. Servedio, R. Carbone, A. Totaro, M. Carella, S. Perrotta, S.N.
Wickramasinghe, J. Delaunay, H. Heimpel, P. Gasparini, Geographic distribution
of CDA-II: did a founder effect operate in Southern Italy? Haematologica 85
(2000) 470–474.
[106] P. Gasparini, E. Miraglia del Giudice, J. Delaunay, A. Totaro, M. Granatiero, S.
Melchionda, L. Zelante, A. Iolascon, Localization of the congenital dyserythro-
poietic anemia II locus to chromosome 20q11.2 by genomewide search, Am. J.
Hum. Genet. 61 (1997) 1112–1116.
[107] E.A. Eklund, H.H. Freeze, The congenital disorders of glycosylation: a multi-
faceted group of syndromes, NeuroRx 3 (2006) 254–263.
[108] K. Panneerselvam, H.H. Freeze, Mannose corrects altered N-glycosylation in
carbohydrate-deﬁcient glycoprotein syndrome ﬁbroblasts, J. Clin. Invest. 97
(1996) 1478–1487.
[109] M. Brockington, F. Muntoni, The modulation of skeletal muscle glycosylation as a
potential therapeutic intervention inmuscular dystrophies, ActaMyol. 24 (2005)
217–221.
[110] R. Barresi, D.E. Michele, M. Kanagawa, H.A. Harper, S.A. Dovico, J.S. Satz, S.A.
Moore, W. Zhang, H. Schachter, J.P. Dumanski, et al., LARGE can functionally
bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular
dystrophies, Nat. Med. 10 (2004) 696–703.
[111] P.T. Martin, Mechanisms of disease: congenital muscular dystrophies-glycosyla-
tion takes center stage, Nat. Clin. Pract. Neurol. 2 (2006) 222–230.
